EGFR and non-small cell lung carcinoma: Osimertinib has demonstrated superiority over first-generation TKIs such as gefitinib and erlotinib in treatment-naïve advanced NSCLC [11] and has also proven more effective than chemotherapy with platinum-pemetrexed therapy in patients with disease progression after initial first-line EGFR-TKI treatment failure [12].